CARLSBAD, Calif. – Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, announced the receipt of a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits, from Factor Bioscience Inc. (“Factor”). Generation of the line marks a successful milestone in the strategic collaboration between the two companies, under which Factor developed a proprietary, genetically engineered iPSC line that Lineage can utilize for differentiation into certain cell transplant product candidates. [Read more…]
Can Stem Cells Treat an ACL Tear or Torn Meniscus?
Can stem cell therapy be used to treat an ACL tear or torn meniscus? While these injuries are traditionally treated using invasive orthopedic surgeries, stem cells are now emerging as a therapeutic alternative.
In this article:
Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies
Belgium, Mont Saint-Guibert, 13 January 2026 – Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new iPSC-derived GMP cell therapy manufacturing platforms: Echo™-T, Echo™-Cardio, and Echo™-Endothelial. The new platforms are designed to advance cell therapies and drive progress across immuno-oncology and regenerative medicine.Building on the success of the Cellistic Echo™-NK manufacturing platform for natural killer (NK) cells, the expanded Cellistic Echo™ portfolio leverages the company’s GMP manufacturing expertise and its EMA-certified, FDA- and PMDA-compliant manufacturing facility. Through dedicated platform development, these capabilities are extended to deliver scalable solutions across additional immune and regenerative cell types.
[Read more…]
WORD+2026 Connecting Global NAM Research. #Bettertogether Organoids, Organ-on-a-Chip, Assembloids and innovative NAMS.
In just three weeks time, the 5th WORD+ event brings together leading researchers, societies and technologies in Cambridge, U.K. February 4th and 5th sees over 40 research talks from academia, pharmaceutical & industry. Uniquely open, fun and collaborative, prices are supported for researchers to attend. See all chairs and speakers here [Read more…]
Changing Dynamics in Umbilical Cord Blood and Tissue Banking
Cord blood is the blood that remains in the umbilical cord after the delivery of a newborn. It is a rich source of stem cells and immune system cells. During cord blood banking, these cells are isolated and cryopreserved for future use. The cells are collected from the two arteries and the vein which run along the length of the umbilical cord. The Wharton’s jelly is a gelatinous tissue that composes the umbilical cord, which also contains valuable therapeutic cells such as MSCs. [Read more…]
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 334
- Next Page »